Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - Alpha Cognition Inc. (TSXV: ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce the appointment of Lauren D'Angelo to Chief Commercial Officer. In this role, she will ensure the integrated commercial success of the company. Her initial focus will be to establish the company's commercial strategy to effectively advance and position Alpha Cognition's neurology pipeline, which includes leading all aspects of the U.S. commercial launch of the company's lead program, ALPHA-1062, pending regulatory approval.
"Ms. D'Angelo joins our team at an important point in the company's history," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "She has more than 20 years' biopharmaceutical commercial experience and direct leadership launching successful products and driving brand growth. Her hands-on experience in building high-performing teams, capabilities and infrastructure to support the commercial launches of innovative new drugs will play a critical role at Alpha Cognition as we accelerate our commercialization efforts this year."
"I joined Alpha Cognition because of ALPHA-1062's potential to become a best-in-class, standard-of-care treatment option for patients suffering from Alzheimer's Disease, a multi-billion dollar market that has lacked innovation for over a decade," said Ms. D'Angelo. "The team at Alpha Cognition share a commitment to pushing scientific boundaries and developing best-in-class medicines. I look forward to joining the Company and to building a commercial organization focused on bringing important new therapies to patients suffering from neurologic disorders."
Ms. D'Angelo has more than 20 years' experience leading successful drug commercialization efforts across 10 therapeutic areas including neurology. She most recently served as Vice President, Marketing and Commercial Strategy at Urovant Sciences, where she joined the company as employee #3, and led the commercial launch of GEMTESA®, the first new Overactive Bladder (OAB) drug treatment in more than 10 years. Prior to Urovant Sciences, Ms. D'Angelo held leadership roles in commercial development, marketing, operations and sales at Avanir Pharmaceuticals, Medivation, Genentech, and AstraZeneca. She has participated in more than 10 successful pharmaceutical drug launches, six of which have become blockbuster brands, including NEXIUM®, CRESTOR®, SYMBICORT®, SEROQUEL XR®, ONGLYZA® and XTANDI®.
Due to Ms. D'Angelo's strong track record of success, she was recognized as Medical Marketing & Media's 2017 Woman to Watch and was selected as one of Pharmaceutical Executive's Emerging Pharma Leaders for 2020. Ms. D'Angelo received her B.S. in Management Information Systems and Finance from Florida State University and her MBA from the University of Florida.
May 6, 2021 Webcast Reminder:
Pursuant to the News Release April 30, 2021, the Company will host a webcast investor presentation on Thursday, May 6th, 2021 at 2:00 PM EDT. During the webcast, Mr. McFadden, Chief Executive Officer, will provide a presentation covering key areas of Alpha Cognition's business. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal. To listen to the webcast or to ask questions during the live event, please pre-register at the following link:
An archived version of the webcast and presentation will be available on the Company's Website: https://www.alphacognition.com/
About Alpha Cognition Inc.
Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).
ALPHA-1062, is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects and novel routes of administration. ALPHA-1062's active metabolites are differentiated from donepezil and rivastigmine in that they may sensitize neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and in a nasal spray formulation to treat traumatic brain injury.
ALPHA-0602 (Progranulin) is expressed in several cell types in the central nervous system and in peripheral tissues, regulates cell survival and certain inflammatory processes, and plays a major role in regulating lysosomal function and microglial responses to disease. Its use for the treatment of neurodegenerative diseases has been patented by the Company and granted an Orphan Drug Designation.
For further information:
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release is not, and under no circumstances is to be construed as, an advertisement or a public offering of securities. No securities commission or similar authority in Canada or in any other jurisdiction has reviewed or in any way passed upon this news release or the merits of the securities described herein and any representation to the contrary is an offence.
This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company's business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.
This news release may also contain estimates and other statistical data made by independent parties and by the Company relating to share value and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/82763